Basel, 05 June 2018 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2018 Tuesday, 31st July 2018 We are pleased to invite you to an analyst event on Tuesday, 31st July 2018 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab... Read more
Basel, 05 June 2018 FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and... Read more
Basel, 03 June 2018 Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Further data demonstrate polatuzumab vedotin’s clinical efficacy across a range of diffuse large B-cell lymphoma subgroups Additional results from the randomised phase III MURANO study support fixed-duration Venclexta/Venclyxto plus MabThera/Rituxan... Read more
Basel, 02 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer Data will be featured in the ASCO press programme on Saturday 2 June and presented at ASCO on Monday 4 June Roche (SIX:... Read more
Basel, 02 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer Data will be featured in the ASCO press programme on Saturday 2 June and presented at ASCO on Monday 4 June Roche (SIX:... Read more
Basel, 01 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence An important new treatment option has been approved for patients in Europe with HER2-positive early breast cancer at high risk of recurrence in a setting where the goal of treatment is cure High... Read more
Basel, 01 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence An important new treatment option has been approved for patients in Europe with HER2-positive early breast cancer at high risk of recurrence in a setting where the goal of treatment is cure High... Read more
Basel, 01 June 2018 Roche to present data for TECENTRIQ (atezolizumab) from across its genitourinary and gastrointestinal cancer immunotherapy programme at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting The data to be presented further demonstrate potential of TECENTRIQ and Avastin combination in renal cell carcinoma, a type of kidney cancer, and hepatocellular... Read more
Basel, 29 May 2018 Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival... Read more
Basel, 25 May 2018 Reminder: Invitation to Roche Analyst Event at ASCO 2018 Monday, 4 June 2018 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June... Read more